Literature DB >> 23919371

Statistical evaluation of the use of concurrent controls in treatment screening studies.

Rickey E Carter1, Qian Shi.   

Abstract

A well-designed pilot study can advance science by providing essential preliminary data to support or motivate further research, refine study logistics, and demonstrate proof of concept. Often, the outcomes of such studies can be quantified by a success/failure dichotomy. For example, a novel compound may show activation of a neural pathway, or it may not. When an intervention's efficacy is quantified using a dichotomous outcome, probability mass functions can be enumerated to determine the probability that the observed result from a pilot study supports further evaluation of the intervention since there is only a finite, and often small, number of sample configurations possible. The purpose of this research was to determine the probability of an "efficacy signal" for pilot studies using one- and two-sample pilot study designs. Efficacy signal was defined as the probability of observing a more favorable response proportion relative to a historical control (one-sample setting) or to a concurrent control (two-sample setting). An enumeration study (exact simulation) was conducted to calculate the efficacy signal probability. One-sample study designs yielded higher probability of determining an efficacy signal than the two-sample setting; however, sampling variation must be accounted for. A 68% score confidence interval is recommended for this purpose.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  confidence interval; pilot study; randomization; study design

Mesh:

Year:  2013        PMID: 23919371      PMCID: PMC3740457          DOI: 10.1111/cts.12042

Source DB:  PubMed          Journal:  Clin Transl Sci        ISSN: 1752-8054            Impact factor:   4.689


  19 in total

1.  The role of the pilot study: a case illustration from cardiac nursing research.

Authors:  N Jairath; M Hogerney; C Parsons
Journal:  Appl Nurs Res       Date:  2000-05       Impact factor: 2.257

2.  From pilot work to a major study in cancer nursing research.

Authors:  P S Hinds; J S Gattuso
Journal:  Cancer Nurs       Date:  1991-06       Impact factor: 2.592

3.  Design issues of randomized phase II trials and a proposal for phase II screening trials.

Authors:  Lawrence V Rubinstein; Edward L Korn; Boris Freidlin; Sally Hunsberger; S Percy Ivy; Malcolm A Smith
Journal:  J Clin Oncol       Date:  2005-10-01       Impact factor: 44.544

4.  Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design.

Authors:  Jeremy M G Taylor; Thomas M Braun; Zhiguo Li
Journal:  Clin Trials       Date:  2006       Impact factor: 2.486

Review 5.  The design and interpretation of pilot trials in clinical research in critical care.

Authors:  Donald M Arnold; Karen E A Burns; Neill K J Adhikari; Michelle E Kho; Maureen O Meade; Deborah J Cook
Journal:  Crit Care Med       Date:  2009-01       Impact factor: 7.598

6.  On the use of a pilot sample for sample size determination.

Authors:  R H Browne
Journal:  Stat Med       Date:  1995-09-15       Impact factor: 2.373

7.  Statistical considerations for pilot studies.

Authors:  D Schoenfeld
Journal:  Int J Radiat Oncol Biol Phys       Date:  1980-03       Impact factor: 7.038

8.  Randomized phase II trials: time for a new era in clinical trial design.

Authors:  Sumithra J Mandrekar; Daniel J Sargent
Journal:  J Thorac Oncol       Date:  2010-07       Impact factor: 15.609

9.  Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study.

Authors:  Elaine Weiner; Alison Buchholz; Agnes Coffay; Fang Liu; Robert P McMahon; Robert W Buchanan; Deanna L Kelly
Journal:  Schizophr Res       Date:  2011-03-04       Impact factor: 4.939

Review 10.  Research Domain Criteria: cognitive systems, neural circuits, and dimensions of behavior.

Authors:  Sarah E Morris; Bruce N Cuthbert
Journal:  Dialogues Clin Neurosci       Date:  2012-03       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.